An Affordable Screen For
Breast and Ovarian Cancer Risk

The BRCA gene test is a DNA analysis to identify harmful changes (mutations) in either one of the two breast cancer susceptibility genes.  The genes associated with hereditary breast and ovarian cancer are called BRCA1 and BRCA2.  Women who have inherited mutations in these genes face a much higher risk of developing breast cancer and ovarian cancer compared to the general population.

MyBRCA™ identifies the three most common germ line mutations. 

Who should consider MyBRCA™?

According to the Mayo Clinic:

  • A personal history of breast cancer diagnosed at a young age (premenopausal), breast cancer affecting both breasts (bilateral breast cancer), or both breast and ovarian cancers 
  • A personal history of ovarian cancer and a close relative with ovarian cancer or premenopausal breast cancer or both 
  • A history of breast cancer at a young age in two or more close relatives, such as your parents, siblings and children 
  • A male relative with breast cancer 
  • A family member who has both breast and ovarian cancers 
  • A family member with bilateral breast cancer 
  • Two or more relatives with ovarian cancer 
  • A relative with a known BRCA1 or BRCA2 mutation 
  • Ashkenazi (Eastern European) Jewish ancestry, with a close relative who has breast or ovarian cancer 
  • Ashkenazi Jewish ancestry and a personal history of ovarian cancer

Soon we will offer MyBRCA+™,an expanded screen encompassing the six most prevalent founder mutations

If a patients tests positive for BRCA, we offer a full genome reflex test, MyBRCA-NGS™. This Next Generation Sequence test identifies the presence of additional mutations in BRCA and in other oncogenes and tumor suppressors that affect your risk.